Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial
T Vesikari, JM Langley, N Segall, BJ Ward… - The Lancet Infectious …, 2021 - thelancet.com
… The aim of this study was to compare the SPR of a tri-… , and has a favourable safety profile
has important public health … use of TAV in adults, including older adults with controlled chronic …
has important public health … use of TAV in adults, including older adults with controlled chronic …
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled …
…, GM Glenn, 2019nCoV-101 Study Group - PLoS …, 2021 - journals.plos.org
… Here, we report on the phase 2 safety and immunogenicity, … An ad hoc analysis was conducted,
comparing the … acceptable safety/tolerability profiles in adults and/or older adults against …
comparing the … acceptable safety/tolerability profiles in adults and/or older adults against …
Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26. RSV. preF) in adults aged …
K Williams, AR Bastian, RA Feldman… - The Journal of …, 2020 - academic.oup.com
… However, this comparison is limited by the lack of standardized neutralizing assay used
in … of the overall older adult population. Safety and immunogenicity profile of the Ad26.RSV.preF …
in … of the overall older adult population. Safety and immunogenicity profile of the Ad26.RSV.preF …
[HTML][HTML] Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 …
R Izikson, D Brune, JS Bolduc, P Bourron… - The Lancet …, 2022 - thelancet.com
… HD) and a mRNA-1273 vaccine booster dose in older adults. … co-administered group compared
with those who received … The safety and immunogenicity profiles described here for QIV-…
with those who received … The safety and immunogenicity profiles described here for QIV-…
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults …
…, V114-021 (PNEU-FLU) Study Group - Human Vaccines & …, 2022 - Taylor & Francis
… Based on subgroup analyses, safety profiles across the two vaccine groups were generally
… immune responses in older adults (65–74 years and ≥75 years) compared with younger …
… immune responses in older adults (65–74 years and ≥75 years) compared with younger …
[HTML][HTML] A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose …
…, K Bickham, V114-029 PNEU-PED study group - Vaccine, 2023 - Elsevier
… This pivotal phase 3 study compared safety and immunogenicity of V114 and PCV13. … In
conclusion, data from this pivotal V114 trial suggest V114 has an acceptable safety profile, is …
conclusion, data from this pivotal V114 trial suggest V114 has an acceptable safety profile, is …
[HTML][HTML] Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through< 18 years of age: a randomized controlled phase II …
…, A Pandey, V Landolfi, I DeBruijn, QHD04 Study Group - Vaccine, 2021 - Elsevier
… -HD had non-inferior immunogenicity compared to IIV3-HD for … for the additional B-lineage
strain but similar safety profiles … This was a large dose-ranging study across a wide age range …
strain but similar safety profiles … This was a large dose-ranging study across a wide age range …
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
N Charland, P Gobeil, S Pillet, I Boulay, A Séguin… - npj Vaccines, 2022 - nature.com
… 1 dose-ranging study 32 across the adult age … the Older Adult population, as compared to
the Healthy Adult cohort 47 . Overall, these Phase 2 data contribute to the overall safety profile …
the Healthy Adult cohort 47 . Overall, these Phase 2 data contribute to the overall safety profile …
[HTML][HTML] … , randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in …
F Martinon-Torres, J Wysocki, L Szenborn… - Vaccine, 2023 - Elsevier
… the two additional serotypes compared with PCV13, with comparable safety profile. These
… of morbidity and mortality worldwide in both older adults and young children, causing non-…
… of morbidity and mortality worldwide in both older adults and young children, causing non-…
[HTML][HTML] A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up …
…, K Bickham, V114-024 PNEU-PLAN study group - Vaccine, 2022 - Elsevier
… The safety and immunogenicity profiles of V114 and … to study entry and the receipt of V114
or PCV13 in this study for children 2–5 years of age compared with those 6–17 years of age. …
or PCV13 in this study for children 2–5 years of age compared with those 6–17 years of age. …